Femilis Slim LNG-IUS (Development)
The small Femilis® Slim with average release of 14 μg per day of LNG over a 5-years has shown to be highly suitable for endometrial suppression in postmenopausal women in combination with parenteral estrogen substitution therapy. The low systemic absorption of LNG could be desirable, thus allowing for maximization of the beneficial effects of ET on organ tissues (e.g. cardiovascular tissues and breast). Use of the LNG-IUS is associated with high patient satisfaction. The risk of breast cancer may not be increased due to the very low systemic levels of the progestogen, in contrast with systemic progestogen administration.
In his clinic in Ghent, Dr. Wildemeersch organizes training sessions for doctors from inside and outside Belgium, interested in learning the anchoring technique of frameless intrauterine devices.
The clinic is specialized in providing precision intrauterine contraception to fulfill women's needs.
